David Walde

7.7k citations
22 papers · 4.8k indexed · 2 hit papers · h-index 16

David Walde

22 papers receiving 4.6k citations

Hit Papers

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alon...2.9k200120262009201750010001.5k2.0k2.5k

Peers

David Walde
Comparison fields: 5 of 113
  • Oncology 3.7k
  • Cancer Research 1.0k
  • Pulmonary and Respiratory Medicine 1.4k
  • Hepatology 303
  • Surgery 901
Replace John Hamm with:
John Hamm United States
Connie Stephens United States
P. Murawa Poland
Stefan Boeck Germany
Henry Q. Xiong United States
Ryan Nelson United States
Faiza Khemissa-Akouz France
Jorge Barriuso United Kingdom
Markus Borner Switzerland
Mark Kozloff United States
David Walde relative to John Hamm United States John Hamm's profile →
Citations per field
00.5×1.5×
John Hamm · 1×
Citations per year

Countries citing papers authored by David Walde

Since Specialization
Citations

This map shows the geographic impact of David Walde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Walde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Walde more than expected).

Fields of papers citing papers by David Walde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Walde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Walde. The network helps show where David Walde may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Walde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Walde Line = papers co-authored together David Walde links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 202315
2 201154
3 201166
4 201047
5 201040
6 2009186
7 200873
8 20078
9
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Groupbreakdown →
20072909
10 200658
11
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Studybreakdown →
2001882
12 19996
13 199893
14 199754
15 199784
16 19973
17 199537
18 19935
19 19915
20 197138

About David Walde

David Walde is a scholar working on Oncology, Anesthesiology and Pain Medicine and Physiology, having authored 22 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), Nausea and vomiting management (5 papers), Neuroendocrine Tumor Research Advances (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Lung Cancer Research Studies (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), Pathogenesis and Treatment of Hiccups (3 papers) and Cancer survivorship and care (3 papers). The work is most often cited by research in Oncology (3.7k citations), Cancer Research (1.0k citations) and Pulmonary and Respiratory Medicine (1.4k citations). David Walde has collaborated with scholars based in Canada, United States and New Zealand. Frequent co-authors include Keyue Ding, Malcolm J. Moore, Steven Gallinger, H. Au, Wendy R. Parulekar, John Hamm, Arié Figer, Daniel de Castro, P. Murawa and David Goldstein. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs, British Journal of Haematology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026